Stay updated on ARGX-113 Safety & Efficacy in Pemphigus Clinical Trial
Sign up to get notified when there's something new on the ARGX-113 Safety & Efficacy in Pemphigus Clinical Trial page.

Latest updates to the ARGX-113 Safety & Efficacy in Pemphigus Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedMajor update: new operating-status notice and a v3.2.0 version release, replacing the old v3.1.0.SummaryDifference4%
- Check23 days agoChange DetectedThe page has been updated to Revision: v3.1.0, replacing the previous v3.0.2.SummaryDifference0.1%
- Check37 days agoChange DetectedUpdated the page from revision v3.0.1 to v3.0.2 and removed the 'Back to Top' element. No substantive content changes were introduced.SummaryDifference0.2%
- Check44 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.2%
- Check52 days agoChange DetectedThe web page has updated its facility name and location to Afula, Israel, and added specific drug information for efgartigimod alfa, while removing previous location details and outdated genetic disease resources.SummaryDifference2%
- Check66 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
Stay in the know with updates to ARGX-113 Safety & Efficacy in Pemphigus Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARGX-113 Safety & Efficacy in Pemphigus Clinical Trial page.